Walvax COVID-19 vaccine

ARCoV
Vaccine description
Target	SARS-CoV-2
Vaccine type	mRNA
Clinical data
Routes of; administration	Intramuscular
Identifiers
DrugBank	DB15855;

AWcorna, originally termed ARCoV^[1] and also known as the Walvax COVID-19 vaccine, is an mRNA COVID-19 vaccine developed by Walvax Biotechnology, Suzhou Abogen Biosciences, and the PLA Academy of Military Science.^[2] In contrast to other mRNA COVID vaccines, such as those by Pfizer-BioNtech and Moderna, this vaccine primarily targets the Sars-CoV-2 receptor-binding domain of the spike protein, rather than the entire spike protein.^[3] It is approved for Phase III trials in China,^[4] Mexico,^[5] Indonesia,^[6] and Nepal.^[7]

It granted emergency use approval in Indonesia in September 2022.^[8]

^ Liu X, Li Y, Wang Z, Cao S, Huang W, Yuan L, et al. (August 2022). "Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults". Cell Research. 32 (8): 777–780. doi:10.1038/s41422-022-00681-3. PMC 9197092. PMID 35701541.
^ "SARS-CoV-2 mRNA vaccine". go.drugbank.com. Retrieved 10 April 2021.
^ Chen GL, Li XF, Dai XH, Li N, Cheng ML, Huang Z, et al. (March 2022). "Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial". The Lancet. Microbe. 3 (3): e193–e202. doi:10.1016/S2666-5247(21)00280-9. PMC 8786321. PMID 35098177.
^ Ma J (22 July 2021). "Domestic clinical trials planned for China's mRNA Covid-19 vaccine". South China Morning Post. Retrieved 23 July 2021.
^ "Mexico to start late-stage clinical trial for China's mRNA COVID-19 vaccine". Reuters. 11 May 2021. Retrieved 14 May 2021.
^ Pinghui Z (1 September 2021). "Indonesia, Mexico approve phase 3 trials of Chinese mRNA vaccine hopeful". South China Morning Post. Retrieved 1 September 2021.
^ "Nepal approves late-stage trials for Chinese mRNA vaccine candidate". Reuters. 27 August 2021. Retrieved 28 August 2021.
^ Widianto S, Liu R (30 September 2022). "A Chinese mRNA COVID vaccine is approved for the first time - in Indonesia". Reuters. Retrieved 18 November 2022.

[:20-1] Liu X, Li Y, Wang Z, Cao S, Huang W, Yuan L, et al. (August 2022). "Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults". Cell Research. 32 (8): 777–780. doi:10.1038/s41422-022-00681-3. PMC 9197092. PMID 35701541.

[:1-2] "SARS-CoV-2 mRNA vaccine". go.drugbank.com. Retrieved 10 April 2021.

[3] Chen GL, Li XF, Dai XH, Li N, Cheng ML, Huang Z, et al. (March 2022). "Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial". The Lancet. Microbe. 3 (3): e193–e202. doi:10.1016/S2666-5247(21)00280-9. PMC 8786321. PMID 35098177.

[:3-4] Ma J (22 July 2021). "Domestic clinical trials planned for China's mRNA Covid-19 vaccine". South China Morning Post. Retrieved 23 July 2021.

[:2-5] "Mexico to start late-stage clinical trial for China's mRNA COVID-19 vaccine". Reuters. 11 May 2021. Retrieved 14 May 2021.

[:5-6] Pinghui Z (1 September 2021). "Indonesia, Mexico approve phase 3 trials of Chinese mRNA vaccine hopeful". South China Morning Post. Retrieved 1 September 2021.

[:4-7] "Nepal approves late-stage trials for Chinese mRNA vaccine candidate". Reuters. 27 August 2021. Retrieved 28 August 2021.

[8] Widianto S, Liu R (30 September 2022). "A Chinese mRNA COVID vaccine is approved for the first time - in Indonesia". Reuters. Retrieved 18 November 2022.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]